Yuksel Nese, Todorova Lora, Scrine Ludmila, Rea Carol, Bouchard Céline
From the University of Alberta, Edmonton, Alberta, Canada.
Astellas Pharma Europe Ltd, Addlestone, United Kingdom.
Menopause. 2025 Jan 1;32(1):38-44. doi: 10.1097/GME.0000000000002451.
The aim of the study was to assess the prevalence of postmenopausal vasomotor symptoms (VMS) and the impact of VMS and related treatment patterns among perimenopausal and postmenopausal Canadian women.
A subgroup analysis of data from a cross-sectional online survey of women aged 40-65 years conducted November 4, 2021, through January 17, 2022, evaluated the prevalence of moderate/severe VMS among postmenopausal Canadian women. The analysis also assessed survey responses from perimenopausal and postmenopausal Canadian women with moderate/severe VMS who completed the Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, and the Patient-Reported Outcomes Measurement Information System Sleep Disturbances-Short Form 8b and answered questions about treatment patterns and attitudes toward treatments.
Of 2,456 Canadian postmenopausal women, 360 (14.7%; primary analysis) reported moderate/severe VMS in the previous month. Perimenopausal and postmenopausal women with moderate/severe VMS (n = 400; secondary analysis) reported negative impact on overall quality of life (mean total Menopause-Specific Quality of Life questionnaire score: 4.3/8). VMS impaired overall work and daily activities by 30.2% and 35.7%, respectively. Overall mean (SD) Patient-Reported Outcomes Measurement Information System Sleep Disturbance-Short Form 8b score (scale 8-40) was 28.5 (6.9), confirming sleep disturbances in this population. The majority of women (88% of the total cohort) sought advice, but about half were never treated. Most women had positive or neutral attitudes toward menopause.
In a survey conducted in Canada, moderate/severe VMS were reported by 14.7% of postmenopausal women and were associated with impairment in quality of life, work productivity, daily activities, and sleep in perimenopausal and postmenopausal women.
本研究旨在评估加拿大围绝经期和绝经后女性中绝经后血管舒缩症状(VMS)的患病率,以及VMS及相关治疗模式的影响。
对2021年11月4日至2022年1月17日进行的一项针对40 - 65岁女性的横断面在线调查数据进行亚组分析,评估加拿大绝经后女性中中度/重度VMS的患病率。该分析还评估了完成更年期特异性生活质量问卷、工作效率和活动障碍问卷以及患者报告结局测量信息系统睡眠障碍简表8b的加拿大围绝经期和绝经后中度/重度VMS女性的调查回复,并回答了有关治疗模式和对治疗态度的问题。
在2456名加拿大绝经后女性中,360名(14.7%;初步分析)报告在前一个月有中度/重度VMS。中度/重度VMS的围绝经期和绝经后女性(n = 400;二次分析)报告对总体生活质量有负面影响(更年期特异性生活质量问卷平均总分:4.3/8)。VMS分别使总体工作和日常活动受损了30.2%和35.7%。患者报告结局测量信息系统睡眠障碍简表8b的总体平均(标准差)得分(范围8 - 40)为28.5(6.9),证实了该人群存在睡眠障碍。大多数女性(占总队列的88%)寻求过建议,但约一半人从未接受过治疗。大多数女性对更年期持积极或中性态度。
在加拿大进行的一项调查中,14.7%的绝经后女性报告有中度/重度VMS,且与围绝经期和绝经后女性的生活质量、工作效率、日常活动及睡眠受损有关。